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Traditional methods for detecting asymptomatic brain changes in neurodegenerative diseases such as Alzheimer’s disease or frontotempor
al degeneration typically evaluate changes in volume at a predefined level of granularity, e.g. voxel-wise or in a priori defined cortical vo
lumes of interest. Here, we apply a method based on hierarchical spectral clustering, a graph-based partitioning technique. Our method uses
multiple levels of segmentation for detecting changes in a data-driven, unbiased, comprehensive manner within a standard statistical frame
work. Furthermore, spectral clustering allows for detection of changes in shape along with changes in size. We performed tensor-based
morphometry to detect changes in the Genetic Frontotemporal dementia Initiative asymptomatic and symptomatic frontotemporal degen
eration mutation carriers using hierarchical spectral clustering and compared the outcome to that obtained with a more conventional voxelwise tensor- and voxel-based morphometric analysis. In the symptomatic groups, the hierarchical spectral clustering-based method yielded
results that were largely in line with those obtained with the voxel-wise approach. In asymptomatic C9orf72 expansion carriers, spectral
clustering detected changes in size in medial temporal cortex that voxel-wise methods could only detect in the symptomatic phase.
Furthermore, in the asymptomatic and the symptomatic phases, the spectral clustering approach detected changes in shape in the premotor
cortex in C9orf72. In summary, the present study shows the merit of hierarchical spectral clustering for data-driven segmentation and de
tection of structural changes in the symptomatic and asymptomatic stages of monogenic frontotemporal degeneration.
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Introduction
In autosomal-dominant neurodegenerative disease, ana
tomical changes in brain structure occur years before symp
tom onset.1–4 In frontotemporal degeneration (FTD), the
most common autosomal mutations are chromosome 9
open reading frame 72 (C9orf72), progranulin (GRN), and
microtubule-associated protein tau (MAPT). Large multicen
tre prospective cohorts such as the Genetic Frontotemporal
dementia Initiative (GENFI) and the ARTFL-LEFFTDS
Longitudinal Frontotemporal Lobar Degeneration study
have led to the discovery of asymptomatic brain changes
in autosomal-dominant FTD.3 This is important for the de
velopment of presymptomatic therapies to determine the
optimal timing of a study intervention and to evaluate study
drug effects.
In previous studies, structural changes were determined
with either voxel-wise comparisons4–6 or an atlas-based ap
proach using regions of interest.3,7,8 In an atlas-based ap
proach, the extent of the volumes of interest is defined a

Significance
level

priori, e.g. at the lobar level or at the level of individual re
gions of the atlas within a lobe. A landmark paper reported
grey matter volumetric changes in the asymptomatic stage in
monogenic FTD3 and related the volume-based morphomet
ric changes to the expected time of symptom onset. In that
study, the segmentation was automated and based on atlas
propagation and fusion.9 The volumes consisted of frontal,
temporal, parietal, and occipital lobe, insula, as well as thal
amus, striatum, hippocampus, and amygdala. When all mu
tation carriers were grouped, 10 years before the expected
symptom onset, the insula and the temporal lobe started to
show volume decreases, and 5 years before symptom onset,
the frontal and parietal lobe and all subcortical structures.
The first changes were seen in C9orf72 expansion carriers
in the thalamus, insula and posterior cortical regions 25
years before the predicted time of onset.
Subsequent volumetric studies using a different method
ology yielded findings that were largely in line with the
Rohrer et al.3 report. Two of these studies5,6 used voxel-based
morphometry (VBM) with statistical parametric mapping
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partitioned from a global-to-local spatial scale, without the
need to define the scale a priori. This is then coupled with a
comprehensive statistical approach that takes into account
the amount and interdependence of the comparisons at the
multiple levels, i.e. in the current report false discovery rate
(FDR). Second, our approach incorporated an analysis of dif
ferent aspects of the segmental structural pattern, namely size
and shape. Previous studies focused exclusively on the identi
fication of between-group differences in segmental size.
However, size alone ignores local patterns of co-variation
that do not change the total size in a segment.
We evaluated the merits of this processing pipeline in
GENFI and investigated whether the recent method could
provide additional information about structural changes in
(a)symptomatic carriers of FTD mutations at different levels
of granularity. We determined the significant differences be
tween the asymptomatic and symptomatic carriers, respect
ively, versus the non-carriers at the level of each segment
from the global-to-local segmentation.

Material and methods
Participants
Data used in the preparation of this article were obtained from
the GENFI (https://www.GENFI.org/). This large multicentre
cohort focuses specifically on members of families where a
known FTD gene mutation occurs, mainly C9orf72 expan
sions (presence of >30 repeats), MAPT mutations and GRN
mutations. GENFI recruits controls and asymptomatic car
riers based on their genetic relation to the FTD patients, as
well as FTD patients from (currently) 24 centres. By recruiting
first-degree relatives, population stratification can be con
trolled for. The study was locally approved by the UZ/KU
Leuven Ethics Committee for Research. After receiving a com
plete description of the study protocol, all participants or their
legal representatives provided written informed consent in ac
cordance with the Declaration of Helsinki.
At the time of the third data freeze, a total of 690 partici
pants had been recruited across all centres. Scans from 55
participants were excluded because of missing data (50) or
imaging artefacts upon visual inspection (5). Volumetric
T1-weighted MRI scans of 118 symptomatic carriers, 267
asymptomatic carriers and 250 non-carriers were included
for the present study. The baseline demographics of the
635 participants are given in Table 1, and the clinical infor
mation of the patients is reported in Table 2. Two-way
ANOVA’s with mutation and genetic status (non-carriers,
asymptomatic, symptomatic) were performed to asses
between-group differences in age, sex and education level.
For age, main effects of mutation (F(2,630) = 7.21, P <
0.001) and genetic status (F(2,630) = 95.1, P < 0.001) were
observed, without interaction (Pinteraction: 0.67). Post hoc
testing revealed that, as expected, the symptomatic carriers
were older than the non-carriers and asymptomatic carriers
(Tukey–Kramer P < 0.05). MAPT participants were younger
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(SPM). Cash et al.6 reported a voxel-wise comparison be
tween asymptomatic and symptomatic carriers respectively,
and non-carriers. In asymptomatic C9orf72 expansion car
riers, atrophy was documented in the thalamus, right super
ior posterior cerebellum, superior temporal and inferior
frontal regions. Changes were subtle in the other asymptom
atic carriers: in GRN and MAPT carriers, no areas survived
correction for multiple comparisons. In a small group of
asymptomatic C9orf72 carriers, Lee et al.5 reported volume
loss in the insula, anterior cingulate, striatum and the medial
pulvinar of thalamus compared to controls. A fourth study
was based on a region-based analysis of cortical thickness
in C9orf72 carriers versus non-carriers from the same fam
ily.10 Thinning of the primary motor cortex was observed
in patients with ALS but not in asymptomatic carriers.
Cury et al.8 studied multivariate shape analysis using a differ
ent method, large diffeomorphic deformation metric map
ping. Longitudinal changes were studied in an a priori
defined region, namely the thalamus. Shape changes in the an
terior portion of the thalamus were detected in asymptomatic
mutation carriers. Finally, a recent study increased the reso
lution of subcortical anatomy using atlas propagation and fu
sion.7 Here, in the C9orf72 expansion carriers the earliest
volume changes were in thalamic subnuclei (pulvinar and lat
eral geniculate), cerebellum and hippocampus (particularly
presubiculum and CA1), amygdala and hypothalamus.
In the present study, we implemented a recently proposed
brain segmentation method based on hierarchical spectral
clustering. Spectral clustering11 is a graph-partitioning tech
nique separating vertices into segments. We have applied it be
fore to study complex morphological changes, i.e. changes in
brain shape and facial morphology as a function of complex
genetic traits12,13 and to study structural MRI changes in
Alzheimer’s disease.14 Hierarchical spectral clustering refers
to spectral clustering at successive levels of granularity, from
a global to a local level of segmentation. It may offer a number
of advantages for the application at hand. A priori the level of
segmentation that optimally captures the structural differ
ences between carriers and non-carriers is unknown.
Hierarchical spectral clustering allows one to segment the
brain in a data-driven manner at different levels of granularity.
In the present study, this segmentation is performed in a binary
manner from level to level for a total of eight levels. The
global-to-local segmentation can be likened to a variation of
the spatial zoom, however, with the important characteristic
that the spatial zooming at each level is determined exclusively
by the similarity of features within a segment. The first levels
correspond to a global view and are sensitive to more distrib
uted general changes. The highest levels correspond to a multifocal view optimally suited for more local changes. It is a priori
unclear which degree of granularity would be optimal to de
tect the first changes. It may be that subtle changes are distrib
uted and best detected when analyzing larger structures, e.g.
whole brain atrophy with widening of the CSF or entire lobes
as in Rohrer et al.3 Alternatively, more specific anatomical re
gions such as medial pulvinar6 may be affected first in a select
ive manner. With hierarchical spectral clustering the brain is
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Table 1 Baseline demographics of the participants of the GENFI cohort used in this study
Asymptomatic carriers

Symptomatic carriers

85 (37: 48)
46.9 (13.8) (23–76)
13.7 (3.1) (5–20)

90 (56: 34)
45 (12.4) (20–68)
14.1 (2.9) (5–20)

56 (35: 21)a
64.9 (7.6) (47–78)a
12.6 (4) (5–22)a

125 (52: 73)
47.9 (14.3) (19–86)
14.1 (3.9) (5–24)

129 (45: 84)
46.6 (11.7) (20–76)
14.5 (3.5) (8–24)

42 (20: 22)a
63.3 (9.1) (33–79)a
10.8 (3.9) (5–18)a

40 (21: 19)
44.3 (12.6) (20–71)a
13.9 (3.4) (5–24)

48 (19: 29)
40.8 (10.6) (21–74)a
14 (3.2) (5–20)

20 (13: 7)a
57.3 (7.7) (38–69)a
13.1 (4.2) (5–20)a

number of subjects, N (M:F); age and education (years), mean (std) (min–max); N, number; M, males, F, females.
a
significant difference from other groups with Tukey–Kramer P < 0.05.

Table 2 Clinical information of the patients of the GENFI cohort in this study
C9orf72 (n = 56)

GRN (n = 42)

MAPT (n = 20)

Clinical diagnosis
bvFTD
FTD-ALS
ALS
PPA
CBS
PSP
Dementia-NOS

73.21% (41)
8.93% (5)
7.14% (4)
5.36% (3)
—
1.79% (1)
3.57% (2)

52.38% (22)
—
—
40.48% (17)
4.76% (2)
—
2.38% (1)

100% (20)
—
—
—
—
—
—

Age at onset
Disease duration
MMSE (/30)
CBI-R (/180)
FRS (0-100%)
ALSFRS-R (/48)

59.3 (8.7) (40–74)
5.4 (4.2) (0.8–20.4)
23.3 (6.2) (0–30)
65.7 (30.3) (5–129)
36.8% (26.6%) (0–97%)
37.5 (8.5) (20–45)

61.2 (7.8) (48–77)
2.8 (1.9) (0.1–10.1)
20.0 (6.1) (7–29)
60.3 (32.3) (11–126)
40.5% (26.3%) (4–97%)
N/Aa

52.3 (6.2) (37–66)
5.0 (4.8) (0.2–17.4)
25.6 (4.1) (16–30)
59.0 (37.6) (4–120)
49.2% (30.1%) (7–100%)
N/Aa

Clinical diagnosis: phenotype: percentage within genetic group (N); mean age at onset and disease duration in years (std) (min–max); MMSE, Mini-Mental State Examination; CBI-R,
Cambridge Behavioural Inventory—Revised, FRS, FTD Rating Scale; ALSFRS-R, ALS Functional Rating Scale-Revised, for MMSE, CBI-R, FRS and ALSFRS-R the mean score is reported
and (std) (min–max). bvFTD, behavioural variant of frontotemporal degeneration; ALS, amyotrophic lateral sclerosis; PPA, primary progressive aphasia; NOS, not otherwise specified;
PSP, progressive supranuclear palsy; CBS, corticobasal syndrome.
a
only administered if a patient is diagnosed with (FTD-)ALS.

than other mutation groups. There was also a significant
main effect of status when modelling education (F(2,630) =
15.52, P < 0.001), with post hoc testing showing that the
symptomatic carriers on average had fewer years of educa
tion than the asymptomatic carriers and non-carriers.
There was also a main effect of status on sex in our cohort
(F(2,630) = 5.62, P = 0.004), with more male participants
in the symptomatic carrier group compared with the asymp
tomatic carriers and non-carriers groups. In all our analyses,
age, sex, family membership and study site were included as
covariates of no interest (analogous to Cash et al.6).

Acquisition and preprocessing of the
MRI data
Volumetric MRI acquisition
The GENFI imaging protocol comprises a set of standar
dized MRI sequences to be used across the different study

sites. In the majority of participants baseline volumetric
T1-weighted MRI were acquired using 3 T scanners (n =
587) [GE (25), Philips (242), Siemens (320)]. In the remain
der, when there was no 3 T scanner available at the centre,
scans were acquired on 1.5 T (n = 48) [GE (9), Siemens
(39)] scanners.

Preprocessing
Tensor-based morphometry (TBM) maps were generated
using the CAT12 toolbox (Structural brain mapping
group, Jena, Germany, http://www.neuro.uni-jena.de/
cat), an extension of SPM12 (Wellcome Trust Centre for
Neuroimaging, London, UK, http://www.fil.ion.ucl.ac.uk/
spm). Segmentation was performed in CAT12 using a de
fault tissue probability map. Local adaptive segmentation
was used at default strength (medium) and Diffeomorphic
Anatomical Registration Through Exponentiated Lie
Algebra15 was used for registration to the default template
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Segmental tensor-based
morphometry
Global-to-local segmentation
Global-to-local tensor-based segmentation was performed
using hierarchical spectral clustering12–14 based on the
Jacobian maps derived from the scans of all participants
(symptomatic and asymptomatic carriers, as well as noncarriers, Supplementary Figure 1). We included the scans
of all participants, whether they were carriers or not. The
segmentation of brain shape (estimated from Jacobian
maps) in a population sample should be stable and reprodu
cible. Since the proposed segmentation was defined at the le
vel of a population (and not at the level of an individual
image), the population sample size becomes crucial and
therefore the segmentation was defined on the complete
data available within the GENFI cohort. Importantly, in
our case no categorical disease labels were used as the seg
mentation was unsupervised.
Spectral clustering aims to organize voxels into clusters
with high within-cluster and low between-cluster data rela
tions. Specifically, this was done using the (spectral) eigendecomposition of a square affinity matrix A (number vox
els × number voxels) expressing all pair-wise data rela
tions.11 In this work (and following Gors et al.14), based
on all 635 MRI scans, the pair-wise relationship between
two voxels i and j was set equal to: A(i,j) = 0.5(corr(Ji, Jj) +
1), with Ji the Jacobian vector over each subject’s Jacobian
map at the ith voxel. Negative/positive correlations generated
a low/high affinity between voxel pairs. Pairs with high affin
ity are likely to cluster together, and pairs with low affinity
are likely to cluster differently. Subsequently, the matrix A
was transformed into a Laplacian matrix L=D-1/2 AD-1/2,
from which the eigenvectors associated with the k (k = 2,
for a split into two clusters) highest eigenvalues were taken.
D is a diagonal matrix, where di, i represents the sum of the ith
column of the matrix A. This transformation of A into L fol
lowed by an eigen-decomposition enhances the (dis)similar
ities of voxel pairs in A, and therefore simplifies the
partitioning problem of voxels into clusters. In the eigen
vector space, the Euclidean distance, serves as a proxy for

the affinity, and drives a k-means clustering to partition the
vertices into two clusters. Computationally, these operations
are not straightforward since the construction of the matri
ces A and L was not possible due to memory constraints
when working with over 5 × 105 voxels. This was solved
using Nyström17 which is a technique that simultaneously
estimates the Laplacian and the eigenvectors of a large-scaled
matrix using only a random subset of its columns. Finally,
due to the random behaviour in k-means and Nyström, a
two step-robustness procedure was implemented. The first
step averaged multiple Nyström estimations (n = 50) result
ing from randomly different voxel subsets. In the second
step, k-means was repeated 50 times and the produced clus
ters are merged into a single partitioning with a normalized
vote-weighting scheme.18
A hierarchical spectral clustering was obtained by sequen
tially splitting a segment into two disjoint segments, whereby
each new segment independently of the other is further parti
tioned into two and so on. From one level to the next, a bin
ary segmentation was performed, i.e. two segments in the
lower level for every parent segment, for a total of eight le
vels. The first level contained the entire intracranial volume.
The second level consisted of two segments, going up to 27
segments at the highest eighth level (Fig. 1A).

Statistical analyses
Jacobians within each segment of the global-to-local segmenta
tion were summarized as segmental size features and segmental
shape coefficients. Segmental size was computed as the average
Jacobian across all voxels within a segment. Segmental shape
coefficients were calculated as follows: first, we corrected for
segmental size by dividing the Jacobian values of a segment
by its size (i.e. the average Jacobian). After this division, the
shape space was computed using principal component analysis
(PCA, singular value decomposition). Besides the resulting di
mensionality reduction, PCA has the advantage that linear
combinations of the principal components enable a recon
struction of the original space. Parallel analysis19 was used
to determine the significant principal components.
Within each segment structural differences between the
asymptomatic FTD mutation carriers versus non-carriers,
and symptomatic FTD mutation carriers versus non-carriers
were determined to study the potential of the new method
(Fig. 1B). Hierarchical spectral clustering is then coupled
with a comprehensive statistical approach that takes into ac
count the amount and interdependence of the comparisons.
Between-group differences in size were analyzed using
Student’s t tests (assuming equal variance). Differences in
shape, which is a multivariate feature, were tested using ca
nonical correlation analysis (CCA). Testing was performed
separately on all 255 segments (of the eight levels) of the hier
archical segmentation. The FDR-adjusted significance thresh
old was computed at P = 0.0007 (‘dep’,20 (α < 0.05)). The
threshold considers the number of contrasts (n = 6), the num
ber of form features (size and shape, n = 2), as well as the
number of segments (n = 255). It means that 12 tests on
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(IXI555 MNI152). The determinant of the gradients of the
deformation field in every voxel resulted in the Jacobian
maps, encoding the structural information that was used
for tensor-based image segmentation. Voxel size was set at
1.5 mm (isotropic) after internal resampling at 1 mm.
Images were smoothed using a 6 × 6 × 6 mm3 Gaussian ker
nel (for comparison to Cash et al.6). Quality of the raw data
was verified by means of the CAT12 Image Quality Ratio
(IQR) combining measures of noise, inhomogeneity and
resolution.16 Quality of the segmentation step was verified
by estimating sample homogeneity of the Jacobian maps
using the CAT12 toolbox, which was calculated by correlat
ing each individual map to the rest of the sample.

R. Bruffaerts et al.

Hierarchical spectral clustering in FTD

BRAIN COMMUNICATIONS 2022: Page 7 of 16

| 7

Hierarchical
Spectral
Clustering

Jacobian maps of
carriers & non-carriers
(n = 635)

B

Global-to-local segmentation
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per segment

Shape
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Segment from global-to-local
segmentation
(n = 255)
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Figure 1 Schematic of workflow. (A) Global-to-local segmentation with visualization of the 1st to 6th level of the hierarchical segmentation
with circular dendrograms (3th to 8th level is visualized in Supplementary Figure 2 for completeness and 3D images were uploaded as
Supplementary data). Intra-segment voxels are randomly coloured according to their position in hierarchical diagrams. For each segment, the
transversal plane with the highest number of intra-segment voxels is visualized. (B) Statistical analysis of size and shape components per segment,
calculated respectively by means of a Student’s t test comparing the average Jacobians and CCA comparing the principal components (PCs), and
link to the circular dendrogram summarizing significance levels across segments (−log10 P-value).

255 segments are performed simultaneously corresponding
to the abovementioned P threshold. Age, sex, image acquisi
tion site and family membership were added to all analyses as
covariates of no interest.6 Local deformations were estimated

using the Jacobian determinant, whereas ignoring the affine
part of the deformation field. Thus, additional correction
for total intracranial volume was not required because only
non-linear deformation was taken into account.21
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Univariate morphometric analysis

Exploratory analysis of global-to-local
segment results
The patients presented with different clinical phenotypes de
pending on their mutation (Table 2). To determine whether
all clinical phenotypes contributed equally to the
global-to-local segment results in the symptomatic groups,
we calculated thresholded maps for size and shape. The thre
sholded maps were calculated as follows: a binary voxel-wise
map was generated for every level indicating which segments
passed the preset FDR-corrected threshold. Maps were
summed across all 8 levels, resulting a pattern for size and a
pattern for shape for every mutation. The thresholded maps
were used to weight the Jacobian values per voxel resulting
in an average weighted Jacobian value for each individual.
Within the symptomatic carriers, ANOVA’s were conducted
for the C9orf72 and GRN group to determine the effect of
clinical phenotype (in the MAPT group, all symptomatic in
dividuals exhibited the same phenotype, bvFTD).
Finally, we determined the relationship between the size
and shape changes. The pair-wise Dice coefficient was calcu
lated between every mutation group per genetic status
(asymptomatic, symptomatic) to compare the overlap of
the thresholded maps for size and shape. For the purpose
of this comparison, the voxel-wise maps generated for every
level were concatenated instead of summed to serve as binary
input for calculation of the dice coefficients.

Data and code availability
The input data can be requested as the third data freeze from
the GENFI (http://www.GENFI.org/). SPM12 (https://www.
fil.ion.ucl.ac.uk/spm/software/spm12/) and the CAT12 tool
box (http://www.neuro.uni-jena.de/cat/) are freely available
online. The in- house Matlab routine to perform hierarchical
spectral clustering can be downloaded from https://gitlab.
kuleuven.be/u0064036/hierarchical-spectral-clustering.

Results
Data quality
Mean image quality was assessed as ‘good’ using the CAT12
IQR16 (mean IQR: 2.15, s.d. 0.31). A two-way ANOVA
with mutation and genetic status (non-carriers, asymptomat
ic, symptomatic) to assess between-group differences in IQR
showed differences for genetic status (F(2,630) = 29.6, P <
0.001). Post hoc testing revealed that the symptomatic indi
viduals had lower image quality, but this effect disappeared
when age was added as a covariate (genetic status: P = 0.213,
age: P = 0.005).
Sample homogeneity for the Jacobian maps was on aver
age 0.85 (s.d. 0.02). A two-way ANOVA with mutation
and genetic status to assess between-group differences in
homogeneity showed differences for mutation group
(F(2,630) = 7.96, P < 0.001). Post hoc testing demonstrated
that the MAPT group had higher sample homogeneity, but
this effect disappeared when age was added as a covariate
(mutation: P = 0.710, age: P = 0.288) (recall that the
MAPT group was younger).

Global-to-local segmentation
The hierarchical spectral clustering algorithm resulted into
255 segments across the eight hierarchical levels. Fig. 1A dis
plays the first six levels of the segmentation as orbits of a den
drogram: the level of granularity increases when moving
towards the outer orbits. The first level corresponds to the
entire intracranial compartment. The second level results
from a binary segmentation into a compartment largely
made up of the CSF and a brain compartment. The projec
tion of the segments of the levels 3–8 onto the normalized
brain is shown in Supplementary Figure 2.

Hypothesis testing
For each of the 255 segments, the statistical significance of a
segmental size and shape difference between the asymp
tomatic or the symptomatic carriers of the FTD mutations
respectively versus non-carriers was determined. The re
sults are projected on the dendrograms of Figs. 2–5.
These overlays represent the same segmentation as shown
in Fig. 1A but now the colours at each position in the den
drogram depict the segmental P-value, when statistically
significant. Only results surviving FDR correction
(‘dep’20) are reported. These representations allow us to
examine if the genetic mutation has a relatively global or
relatively local impact on brain structure depending on
the position of the effect on the dendrogram. Because of
the hierarchical organization of the segmentation, the re
sults found in parent and child segments are derived on ei
ther the ensemble (parents) or a partition (children) of the
same data. The dendrograms on the right-hand side aid in
identifying the level of optimal granularity, i.e. the level
at which the result is the strongest. Evidently, significant
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The global-to-local segment results were compared with
those obtained for the same contrasts using well-established
(univariate) VBM and TBM to compare the sensitivity of
our method to the standard procedure. Using SPM12, symp
tomatic carriers and asymptomatic carriers of every genetic
group were compared with non-carriers using a one-way
between-subject ANOVA. The same covariates (age, sex,
acquisition site and family membership) were used as in
the multivariate approach. Total intracranial volume was
added as a covariate for VBM. The FDR-adjusted signifi
cance threshold was computed at P = 0.0003 (‘dep’,20 (α <
0.05)), considering the number of contrasts (n = 6), the num
ber of form features (size and shape, n = 2), as well as the
number of segments (n = 255). For comparison to the hier
archical spectral clustering analysis, we only report clusters
larger than 500 voxels because the smallest segment in the
eighth level of segmentation contained 563 voxels.
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Figure 2 Asymptomatic carriers C9orf72 versus non-carriers. Global-to-local segment results for A size and B shape and their respective
dendrograms. Asterisk indicates FDR-adjusted significance (dep) P = 0.0007, −log P = 3.17, results below the FDR-adjusted significance threshold
are not illustrated. Nodes can be linked to their spatial coverage via Fig. 1A. Results from other levels are shown in Supplementary Figure 3.
(C) VBM and TBM analysis: asterisk indicates FDR-adjusted significance (dep) P = 0.0003, t = 3.46. Note that the by convention, only atrophy is
visualized so widening of the ventricles cannot be assessed from the univariate results.

results may sometimes occur in parent or child segments of
the segment with optimal granularity, caused by these
shared datapoints.

C9orf72 asymptomatic carriers versus non-carriers
Using spectral clustering, significant size differences were
found in the posteromedial thalamus but also in the medial
temporal cortex, the striatum, the insula and orbitofrontal
cortex (Fig. 2A). In asymptomatic carriers of C9orf72 ex
pansions versus non-carriers, shape changes were observed
in the motor cortices, inferior frontal gyri and in the white
matter of the occipital lobes (Fig. 2B). A univariate voxelwise VBM and TBM analysis showed posterior thalamic at
rophy but no other abnormalities in C9orf72 asymptomatic
carriers (Fig. 2C).

C9orf72 symptomatic carriers versus non-carriers
The global-to-local segment results were topographically
similar to those found in the asymptomatic group, but
more pronounced size changes were observed when compar
ing the symptomatic carriers to the non-carriers (Fig. 3A).
Similarly, shape changes in the motor cortex were highly sig
nificant in the group of symptomatic carriers (Fig. 3B), ac
companied by widespread changes predominantly in the

frontal lobes (compared with non-carriers) but extending
to other regions as well. A univariate voxel-wise VBM and
TBM analysis demonstrated extensive atrophy in the frontal
and anterior temporal lobes, as well as the basal ganglia com
pared with the non-carriers (Fig. 3C).

GRN carriers versus non-carriers
In the asymptomatic GRN carriers, univariate analysis and
global-to-local segment results did not reveal any differences
with the non-carriers. Using spectral clustering, widespread
size differences were found at all segmental levels when com
paring symptomatic carriers to non-carriers, with a predom
inance in the prefrontal grey and white matter (Fig. 4A). The
spectral clustering analysis showed that symptomatic GRN
mutation carriers displayed widespread shape changes in
the frontal and parietal regions (including the precuneus),
as well as the cerebellum (Fig. 4B). The changes in symptom
atic carriers versus non-carriers were already detected at the
2nd global level of segmentation and persisted at higher le
vels. By means of univariate analysis, GRN symptomatic car
riers demonstrated extensive atrophy in the frontal and
anterior temporal lobes, as well as the basal ganglia com
pared with non-carriers (Fig. 4C).
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Figure 3 Symptomatic carriers C9orf72 versus non-carriers. Global-to-local segment results for A size and B shape and their respective
dendrograms. Asterisk indicates FDR-adjusted significance (dep) P = 0.0007, −log P = 3.17, results below the FDR-adjusted significance threshold
are not illustrated. Nodes can be linked to their spatial coverage via Fig. 1A. Results from other levels are shown in Supplementary Figure 4.
(C) VBM and TBM analysis: asterisk indicates FDR-adjusted significance (dep) P = 0.0003, t = 3.46.
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Figure 4 Symptomatic carriers GRN versus non-carriers. Global-to-local segment results for A size and B shape and their respective
dendrograms. Asterisk indicates FDR-adjusted significance (dep) P = 0.0007, −log P = 3.17, results below the FDR-adjusted significance threshold
are not illustrated. Nodes can be linked to their spatial coverage via Fig. 1A. Results from other levels are shown in Supplementary Figure 5.
(C) VBM and TBM analysis: asterisk indicates FDR-adjusted significance (dep) P = 0.0003, t = 3.46.

Downloaded from https://academic.oup.com/braincomms/article/4/4/fcac182/6645830 by guest on 25 October 2022

Shape differences

B

Hierarchical spectral clustering in FTD

-30

-18

-6

6

18

30

42

54

| 11

66

-log 10 P
5

Layer 6

-42

Layer 8

Size differences

A

BRAIN COMMUNICATIONS 2022: Page 11 of 16

*

Layer 8

Layer 6

-log 10 P
5

*

VBM

t

t
10

TBM

Univariate analysis

C

*

Figure 5 Symptomatic carriers MAPT versus non-carriers. Global-to-local segment results for A size and B shape and their respective
dendrograms. Asterisk indicates FDR-adjusted significance (dep) P = 0.0007, −log P = 3.17, results below the FDR-adjusted significance threshold
are not illustrated. Nodes can be linked to their spatial coverage via Fig. 1A. Results from other levels are shown in Supplementary Figure 6.
(C) VBM and TBM analysis: asterisk indicates FDR-adjusted significance (dep) P = 0.0003, t = 3.46.

Microtubule-associated protein tau carriers versus
non-carriers
Univariate analysis and spectral clustering did not reveal any
difference in the asymptomatic MAPT carriers versus the noncarriers. The size analysis in the symptomatic carriers revealed
changes at all segmental levels compared with non-carriers,
with prominent atrophy in the anterior temporal lobe, fronto
basal region and basal ganglia (Fig. 5A). Symptomatic carriers
displayed shape changes in the motor cortices, as well as in the
white matter compared with non-carriers (Fig. 5B). Changes
were identified across all levels of segmentation and focused
on the white matter. The VBM and TBM atrophy pattern in
MAPT symptomatic carriers compared with non-carriers
was slightly different compared with the C9orf72 and GRN
groups with the most pronounced atrophy in the anterior tem
poral lobes, frontobasal region and basal ganglia (Fig. 5C).

Effect of clinical phenotype and
comparison across size and shape
results
Within the thresholded maps for symptomatic partici
pants, we tested whether the distinct clinical phenotypes

differentially contributed to the size and shape differences
(Fig. 6A). For the symptomatic c9orf72 carriers, where size
changes were found in the thalamus and frontotemporal
cortex, differences were observed between the clinical phe
notypes (F(2,53) = 6.58, P = 0.003). Post hoc testing re
vealed that the size changes were more pronounced in the
bvFTD phenotype compared to the (FTD-)ALS phenotype
(Tukey–Kramer P < 0.05). For shape changes, no differ
ences were found between the different C9orf72 pheno
types (F(2,53) = 0.66, P = 0.521). No differences between
phenotypes were found for size or shape changes in the
GRN group (P > 0.242).
Dice coefficients were calculated to compare the overlap
between global-to-local segment results in the asymptom
atic and symptomatic C9orf72 carriers, and the symptom
atic GRN and MAPT carriers (Fig. 6B). The overlap of the
thresholded maps of asymptomatic C9orf72 carriers was
consistently highest with the symptomatic C9orf72 car
riers. Between all symptomatic groups, substantial overlap
was found between the thresholded maps for size differ
ences. We also calculated the overlap between thresholded
maps of size and thresholded maps of shape differences: on
average, their overlap was low (Fig. 6B, mean dice coeffi
cient: 0.18).
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Figure 6 Stratification per disease phenotype and size versus shape results. (A) Jacobians weighted by means of the thresholded maps
for size and shape changes per genetic group. (*) indicates between-phenotype differences within the symptomatic groups (Post hoc comparison
Tukey–Kramer P < 0.05), note that we did not include the non-carriers and asymptomatic carriers in this statistical comparison. Plots were
generated using the Robust Statistic Toolbox.22 (B) Pair-wise Dice coefficients between the thresholded maps for (a)symptomatic C9orf72
carriers (respectively a, s) and symptomatic GRN and MAPT carriers (s). Note that for size × size and shape × shape comparisons, the Dice
coefficient on the diagonal is one (identical) but that the comparison between size and shape results in an asymmetrical matrix with values of <1 on
the diagonal.

Discussion
We applied a recent method based on hierarchical spectral
clustering to analyze a large multicentric data set of struc
tural MRI scans obtained in symptomatic and asymptomatic
autosomal-dominant FTD mutation carriers and non-

carriers. In particular, in asymptomatic C9orf72 expansion
carriers, spectral clustering revealed changes in segmental
size that more conventional methods detected only at the
symptomatic stage. Furthermore, the method allows for ana
lysis of shape and this demonstrated significant changes in re
gions known to be involved in C9orf72 pathophysiology but
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not seen with the conventional methods. Third, spectral clus
tering revealed a large number of significant changes in the
symptomatic phase of FTD mutations that closely corre
sponded to those seen also with the univariate approaches,
thus suggesting that spectral clustering is sensitive to pick
up these known effects as well as additional changes.

Size and shape changes in
asymptomatic individuals

| 13

cortex in this disease which may cause either FTD or
ALS.28 Using fluorine 18-labeled fluorodeoxyglucose posi
tron emission tomographic imaging, hypermetabolism was
observed in this region in the majority of asymptomatic
C9orf72 expansion carriers compared to controls,29 possibly
reflecting neuroinflammation. Given the location near the pri
mary motor cortex and the vulnerability of the upper motor
neuron system in C9orf72, there are strong neurobiological
arguments to consider this difference in shape in the asymp
tomatic and the symptomatic C9orf72 expansion carriers
versus non-carriers as a true-positive effect. Furthermore,
significant changes in shape were present in asymptomatic
carriers in the lateral prefrontal cortex. These widespread
prefrontal changes were more prominent at the sixth level
of segmentation than at the eighth. An interesting next
step would be to derive the segments from this analysis
with the highest significance for detecting presymptomatic
changes (which may be either the sixth or eighth level) and
determine in an independent dataset how well asymptomat
ic individual cases can be discriminated from non-carriers
based on the values obtained in these segments. More gener
ally, a classifier could be trained on a training data set so that
the best segments for classification are defined and then used
in a test set.30 Such individual-level analyses could be used
for early diagnosis, disease progression monitoring31 or to
study the effect of new drugs.
In the asymptomatic MAPT and GRN mutation carriers
no changes were found with the conventional or the novel
methods. Cash et al.6 reported changes in these groups
with VBM in the medial and anterior temporal lobe and
the posterior insula, respectively, but these were limited in
extent and were only present at a low significance threshold.
Bocchetta et al.7 reported discrete abnormalities in these gen
etic groups at a lower significance threshold (FDR correction
using ‘pdep’32), which were also present in our data set at this
threshold: we observed size changes in the precuneus in
MAPT asymptomatic carriers and shape changes in the stri
atum of GRN asymptomatic carriers. One can only speculate
about the reasons why presymptomatic changes are much
harder to detect in these two mutation groups than in
C9orf72 expansion carriers. In MAPT, the phase preceding
the symptomatic phase may be relatively rapidly progres
sive33 so that asymptomatic carriers who are farther re
moved from symptom onset do not yet show detectable
structural changes. In MAPT, grey matter atrophy was ob
served in a subset of asymptomatic carriers.34 Our statistical
analyses, which test between-group differences, may not be
sensitive to atrophy existing only in a small number of parti
cipants. In GRN the changes may be more asymmetrical and
the method as it is currently implemented would not be able
to detect these asymmetries.

Size and shape changes in
symptomatic individuals
In symptomatic GRN mutation carriers the pattern obtained
with hierarchical spectral clustering matched that seen with
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In the asymptomatic phase of C9orf72, the novel method
had a higher sensitivity than voxel-wise methods. These con
ventional methods only revealed abnormalities in the poster
omedial thalamus (or medial pulvinar), in line with a number
of previous reports,5,6,23 while our method additionally
showed highly significant size changes in medial temporal,
orbitofrontal and medial frontal cortex and insula.
Atrophy in the pulvinar, which is part of the limbic system,
has been linked to attentional deficits5 as well as altered
pain perception24 in C9orf72 carriers. Disrupted connectiv
ity of the posteromedial thalamus has been correlated with
more severe behavioural symptoms.25 Atrophy of the orbito
frontal cortex and insula was previously associated with im
paired social cognition in C9orf72 carriers.26 Atrophy of the
medial temporal lobe has been observed in C9orf72 carriers
with the ALS-FTD phenotype, whereas it was absent in car
riers presenting with ALS.27 Here, the size differences were
most prominent in symptomatic C9orf72 carriers presenting
with bvFTD compared with other phenotypes. This is con
sistent with early size changes occurring in regions related
to the bvFTD phenotype in asymptomatic individuals.
The location of changes detected in asymptomatic C9orf72
expansion group corresponded to the location of most
changes found with conventional TBM/VBM in the symp
tomatic group and in the literature.3,6,26 This colocalization
of changes in the asymptomatic group with changes in the
symptomatic group increases the likelihood that the method
identifies the earliest FTD-related changes, although longitu
dinal data is needed to confirm this hypothesis. Interestingly,
highest significance in medial temporal cortex is reached at
the sixth level of segmentation and decreases at the eight level.
This may explain why it remains below the detection thresh
old of voxel-based analyses and demonstrates the value of
varying levels of granularity in the analysis as some changes
may be more readily detectable at a lower level of resolution.
Our findings, which replicate results obtained using a recent
detailed atlas-based method,7 may reflect the fact that the
medial temporal cortex is affected relatively early. The iden
tification of the spatial extent of hippocampal involvement
exemplifies an important advantage of our method which ex
amines brain changes at different levels of granularity based
on a data-driven partitioning algorithm.
There was also a clear advantage of analyzing changes in
shape, which resulted an atrophy pattern distinct from the
size changes. In asymptomatic as well as symptomatic
C9orf72 carriers, changes in shape were detected in pre
motor cortex. There is a known vulnerability of motor
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Comparison to other segment-based
methods
Image segmentation is important to help clinicians and re
searchers to focus on specific regions of the brain.38 In that
sense, our hierarchical segmentation presents a global-to-local
definition of regions to be analyzed statistically. This is a ‘div
ide and conquer’ strategy keeping the multiple testing burden
into account in comparison to voxel-by-voxel-based analyses.
Besides the hierarchical implementation the proposed segmen
tation is also different to related literature in two main aspects.
First, related voxel-based clustering techniques operate at the
level of an individual image, considering the voxels as a collec
tion of datapoints to be grouped based on intensity.38 In con
trast, the proposed clustering is defined at the level of a
population, in which similarity between voxels is expressed
by correlated variance or covariance of voxel features (shape
coded by Jacobians) within the population sample. To the
best of our knowledge, this is the first such population-based
approach, for which some technical challenges related to
data size and complexity were solved in Gors et al.14 Second,
related voxel-based clustering techniques aim at segmenting
anatomically or functionally defined regions, typically evalu
ated against manual expert segmentations. In contrast, the pro
posed segmentation does not aim to segment the brain into
specifically known regions but instead the aim is to group
into population correlated regions. The idea is to provide an
ensemble of correlated datapoints within a single segment as
input to statistical testing paradigms.12,13 Therefore, the seg
mentation proposed is not to be evaluated against expert seg
mentations but tested based on statistical power as illustrated
in this work.
As expected, our results show a significant overlap with prior
findings based on atlas-based methods.3,7,8 Furthermore, our
approach shows how the use of different atlases containing re
gions of interests of different sizes, may lead to conflicting re
sults. The fact that we offer a hierarchical overview of the
significance levels in the form of the dendrogram, increases
the insight into the spatial extent of structural changes irre
spective of a predefined extent based on a particular atlas.

Strengths and future directions
A benefit of a global-to-local segmentation is that it relaxes
the strong dimensionality reduction burden at the global le
vels, which in isolation may lead to loss of information.
Local volumetric patterns are representatively described
(and analyzed) at the local levels. It is therefore not needed
that the local variations are expressed in the form features
of the global levels as well. Furthermore, complete form fea
tures at the global levels would introduce redundancy be
tween the levels and actually counters the analyses of the
global form effects that are equally of interest.
Further extensions and modifications to the hierarchical
spectral clustering method can be foreseen. For instance,
the choice of eight (fixed) levels was based on pragmatic rea
sons, allowing for sufficiently fine-grained analysis, on the
one hand, and, on the other hand, avoiding an inflation of
number of segments and therefore controlling the multiple
testing burden. Importantly, this choice was made a priori.
Conceivably, the number of levels can also be adapted to
the features of the segments themselves, such as homogen
eity. For some segments, such as CSF, the binary subdivision
could stop already at a relatively early level when the seg
ments exhibit homogeneity. Other segments, such as medial
temporal cortex or thalamus, have such an intricate inherent
structure that further segmentation beyond the eighth level
when this is warranted by the homogeneity measure. A re
lated matter is the binary nature of the division of the seg
ments per level. Based on the segmental homogeneity one
could easily imagine a division in multiple segments.

Limitations
To date, we have demonstrated the merit of global-to-local
segmentation in Alzheimer’s disease14 and here in FTD. The
segments in which structural changes were linked to mono
genic FTD, will require further out-of-sample validation in
other genetic FTD cohorts before clinical translation is in or
der. In its current implementation, our technique (including
segmentation, feature extraction and evaluated hypothesis)
is not designed to detect asymmetry, which is typically present
in the brains of the GRN carriers.23 Asymmetry detection
asks for identification of group changes in intra-individual
differences between the left and right hemispheres. A first
step in making the approach adequate for this contrast is
introducing a symmetric segmentation. The second step is de
fining size and shape features that measure the amount of
asymmetry as differences between left and right. In the con
ventional shape space, the symmetric variations explain the
major variability within the Jacobian maps, while the asym
metric variations have only minor contribution to it.
Therefore, parallel analyses retain mainly the symmetricalrelated PCA coefficients. An alternative is to subtract the
Jacobian values of the left part of a segment from the corre
sponding right part of the segment before PCA training.
The resulting shape coefficients represent the pattern of asym
metrical variability within the segment.
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the conventional methods. Furthermore, we found more ex
tensive white matter size differences in the symptomatic
GRN mutation carriers with spectral clustering than with
conventional methods, most significantly so in frontal white
matter. An increased volume of white matter hyperintensi
ties has been reported before in symptomatic GRN muta
tion carriers mainly in the frontal and occipital lobe.35,36
In the asymptomatic GRN mutation carriers, a correlation
has been found between white matter hyperintensity vo
lumes and time to expected disease onset.36 These hyperin
tensities are associated with grey matter atrophy and
biomarker changes (GFAP and NfL).37 In symptomatic
MAPT mutation carriers, the well-known prominent involve
ment of the anterior temporal pole seen with conventional
analyses4,33 was also observed with the hierarchical spectral
clustering approach.
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Conclusions
To summarize, the merits of the hierarchical spectral cluster
ing versus the conventional methods was most evident in the
asymptomatic C9orf72 carriers. This demonstrates the ad
vantage of data-driven segments at varying degrees of granu
larity in their entirety rather than at a voxel level in this
disease. In MAPT and GRN groups, global-to-local segment
results converged with the focal changes also seen with the
conventional univariate method.
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